Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

FDA: Calcitonin Salmon Cancer Risk Possible

Filed March 4th, 2013 admin

The U.S. Food and Drug Administration (FDA) just released a statement stating that an increased risk of cancer with drugs containing calctonin salmon appears probable.

FDA staff reviewers said the risk amplifies concerns about the overall risk of using calcitonin products to treat osteoporosis in post-menopausal women, Yahoo News said. Calcitonin products, which include Unigene Laboratories Inc’s nasal spray and Novartis AG’s Miacalcin injection and nasal spray, are intended to increase the amount of calcium in bones, while limiting the amount of calcium in the blood.

The FDA reviewers said important questions remain about calcitonin salmon’s effectiveness in limiting fractures in the treatment of postmenopausal osteoporosis, Yahoo News said. An advisory panel is expected to meet this week to discuss the products and will likely make a recommendation to the FDA on whether to discontinue the marketing and sales of these products.

The FDA could follow the lead of the European Medicines Agency (EMA), which recommended that long-term use of calcitonin be stopped last year. The EMA made the decision after a review found significant evidence of an increased risk of cancer associated with long-term use of the drugs. The agency concluded that the benefits of calcitonin-containing medicines did not offset their risks in the treatment of osteoporosis and that the drugs should no longer be used to treat the condition, Yahoo News said.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!